The FDA has granted approval for Lipfendra, a revolutionary oral cholesterol medication developed by Merck. This first-of-its-kind pill significantly reduces LDL cholesterol levels by nearly 60%, offering an alternative to traditional injectable treatments. As the first oral PCSK9 inhibitor, Lipfendra is expected to transform the landscape of cholesterol management, particularly for high-risk patients. Experts are weighing in on its effectiveness compared to existing treatments, with the expectation that this powerful new option may enhance cardiovascular care.